Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Uterus: Low-grade endometrial stromal sarcoma with t(X;17)(p11.2;q21.33) MBTD1/CXorf6

Written2014-11Barbara Dewaele, Maria Debiec-Rychter
Department of Human Genetics, KU Leuven, University Hospitals Leuven, Leuven, Belgium/ barbara.dewaele@uzleuven.be; maria.debiec-rychter@med.kuleuven.be

(Note : for Links provided by Atlas : click)

Abstract

Abstract Short communication on t(X;17)(p11.2;q21.33) MBTD1-CXorf67 in low-grade endometrial stromal sarcoma.

Identity

Atlas_Id 6633
Phylum Female organs: Uterus::Low-grade endometrial stromal sarcoma

Classification

Note Low-grade endometrial stromal sarcoma belongs to the uterine tumors of mesenchymal origin. According to the current World Health Organization classification (2013), uterine endometrial stromal and related tumors are categorized as benign endometrial stromal nodules (ESN), low-grade endometrial stromal sarcomas (LGESS), high-grade endometrial stromal sarcomas (HGESS), undifferentiated endometrial sarcomas (UES)and uterine tumors resembling ovarian sex cord tumor. Low- and high-grade endometrial stromal sarcomas are genetically heterogeneous group of tumours, frequently harbouring recurrent chromosomal translocations. The chimeric transcripts reorted so far are JAZF1/SUZ12, YWHAE/FAM22, ZCH7/BCOR, and recombination of PFH1 with JAZF1, EPC1, or MEAF6 (Koontz et al., 2001; Micci et al., 2006;Lee et al., 2012; Panagopoulos et al.2012; Panagopoulos et al., 2013; Oliva et al., 2013).

Clinics and Pathology

Disease Low-grade endometrial stromal sarcoma (LGESS) with t(X;17) translocation
Phenotype / cell stem origin Unknown
Embryonic origin The cellular origin of this low grade sarcoma is unknown, but the tumor cells presumably derive from the early mesenchymal endometrial progenitor cells.
Etiology Unknown.
Epidemiology The true incidence of t(X;17) LGESS is unknown. Two cases in females of respectively reproductive and postmenopausal age have been reported to date (Amant et al.,2003; Dewaele et al, 2014).
Clinics The patients presented with abnormal uterine bleeding and abdominal pain.
CYTOLOGY
Pathology Classical cases of LGESS are composed of cells that morphologically resemble non-neoplastic proliferative-phase or hyperplastic endometrial stromal cells (Chiang and Oliva, 2013). On cut surfaces, the tumor lesions are solid and white-yellowish with a glassy appearance. Hematoxylin and eosin stained slides show myometrial permeation by wormlike masses and frequent lymphatic infiltration. The tumor cells have bland nuclear features with monotonous oval to spindle cells concentrically proliferating around a rich vascular network of arterioles and capillaries. Mitotic figures are rare. By immunohistochemistry, the tumour components are diffusely and strongly positive for CD10 antigen and for oestrogen and progesterone receptors (Oliva et al., 2013).
 
The tumors consist of cellular spindle cells aligned in short intersecting fascicles, without nuclear pleomorphism or atypia, and show rare mitotic figures (H&E; original magnification, x400).
Treatment Surgical resection of the tumor, followed by hormonal treatment
Prognosis The two reported patients showed a relatively indolent clinical course in spite of their metastatic disease (Amant et al.,2003; Dewaele et al, 2014).

Cytogenetics

Cytogenetics
Morphological
Reciprocal t(X;17)(p11.2;q21.33) translocation has been observed in all reported cases.
t(X;17)(p11;q23) G-banding. Arrows indicate chromosome breakpoints.
Cytogenetics Molecular Metaphase FISH analysis of two LGESS cases using BAC RP11-379D19 DNA probe resulted in a split signal, which defined the 17q21.33 translocation breakpoint to the MBTD1 gene (data not shown). Using a panel of fosmid probes, a minimal shared breakpoint region in Xp11.22 could be mapped to position 51.136-51.321 Mb; this region contains three genes (NUDT10, CXorf67 and NUDT11). Whole transcriptome paired-end sequencing of two LGESS on Illumina HiSeq II platform identified CXorf67 as the partner gene on the X chromosome.
One additional LGESS case with the MBTD1-CXorf67 fusion was identified using interphase FISH with probes that map to sequences covering the CXorf67 and MBTD1 genomic loci (Figure 3).
Interphase FISH on paraffin section of a low-grade ESS using SpectrumGreen-labelled (green signal) and SpectrumOrange-labelled (red signal) RP11-379/17q21.33 and RP11-348F1/Xp11.22 BAC probes, which cover the MBTD1 and CXorf67 genes, respectively. Arrows indicate the presence of MBTD1-CXorf67 fusion.
PROBES: BAC clone for MBTD1: RP11-379D19 covering the gene. BAC clone for CXorf67: RP11-348F1 covering the gene

Genes involved and Proteins

Gene NameMBTD1 (mbt domain containing 1)
Location 17q21.33
Dna / Rna The gene consists of 17 exons that span 79.46 kb of genomic DNA in the telomere-to-centromere orientation. The translation initiation codon and the stop codon are predicted to exon 1 and exon 17, respectively. The corresponding wild-type mRNA transcript is 5.3 kb (NM_017643.2). MBTD1 shows high level expression in normal fallopian tube in comparison to medium level expression in normal endometrium.
The MBTD1 gene consists of 17 exons that span 79.46 kb of genomic DNA in the telomere-to-centromere orientation.
Protein The open reading frame is predicted to encode a 628 amino acid protein with an estimated molecular weight of 70 kDa.

Gene NameCXorf67 (chromosome X open reading frame 67)
Location Xp11.22
Dna / Rna The gene consists of 1 exon that spans 1.92 kb of genomic DNA in the centromere-to-telomere orientation. It is entirely nested in another gene, namely in the intron 1-2 of the RP11-348F1.2 non-coding gene (Yu et al., 2005). The corresponding wild-type mRNA transcript is 1.929 kb (NM_203407). CXorf67 is highly overexpressed in normal oocytes in comparison to low-level expression in other tissues, including normal endometrium.
The CXorf67 gene consists of 1 exon that spans 1.92 kb of genomic DNA in the centromere-to-telomere orientation.
Protein The CXorf67 open reading frame is predicted to encode a 503 amino acid protein (NP_981952.1).

Result of the chromosomal anomaly

Hybrid Gene
 
The sequence of the MBTD1-CXorf67 junction is shown, with the structure of the MBTD1-CXorf67 cDNA depicted below (the dashed arrow indicates the fusion point).
Description The t(X;17)(p11.2;q21.33) results in a MBTD1-CXorf67 chimeric gene in which exon 16 of MBTD1 is fused to exon 1 of CXorf67.
Transcript The MBTD1-CXorf67 fusion transcript is 3142 bp in length (2514 bp without UTR and without Stop codon). The MBTD1-CXorf67 fusion formation is correlated with the CXorf67 3' domains overexpression.
Detection The hybrid gene can be visualized by FISH using gene specific probes or by RT-PCR.
Fusion Protein
Description The predicted MBTD1-CXorf67 fusion protein is shown. Red boxes: the FCS and the four MBT domains of MBTD1; grey box: the Serine-rich domain of CXorf67.
Description The MBTD1-CXorf67 fusion transcript is predicted to encode a chimeric protein of 839 amino acids that contains the FCS-type zinc finger domain and the four MBT domains of MBTD1 and the Serine-rich region of CXorf67.
  

To be noted

The aCGH data and gene expression data were submitted to the GEO database (Series GSE46285, SubSeries GSE46284: aCGH data; SubSeries GSE45783: gene expression profiling data).

Bibliography

Recent developments in uterine mesenchymal neoplasms
Chiang S, Oliva E
Histopathology 2013 Jan;62(1):124-37
PMID 23240674
 
Structural studies of a four-MBT repeat protein MBTD1
Eryilmaz J, Pan P, Amaya MF, Allali-Hassani A, Dong A, Adams-Cioaba MA, Mackenzie F, Vedadi M, Min J
PLoS One 2009 Oct 20;4(10):e7274
PMID 19841675
 
Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors
Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, Dal Cin P, Fletcher JA, Sklar J
Proc Natl Acad Sci U S A 2001 May 22;98(11):6348-53
PMID 11371647
 
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma
Lee CH, Ou WB, Mariño-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB,
Proc Natl Acad Sci U S A 2012 Jan 17;109(3):929-34
PMID 22223660
 
Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in
Micci F, Panagopoulos I, Bjerkehagen B, Heim S
Cancer Res 2006 Jan 1;66(1):107-12
PMID 16397222
 
Mesenchymal tumours.
Oliva E, Carcangiu ML, Carinelli SG, Ip P, Loening T, Longacre TA, Nucci MR, Prat J, Zaloudek CJ.
WHO Classification of Tumours of Female Reproductive Organs 2013.
 
Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma
Panagopoulos I, Micci F, Thorsen J, Gorunova L, Eibak AM, Bjerkehagen B, Davidson B, Heim S
PLoS One 2012;7(6):e39354
PMID 22761769
 
Nested genes in the human genome
Yu P, Ma D, Xu M
Genomics 2005 Oct;86(4):414-22
PMID 16084061
 

Citation

This paper should be referenced as such :
Barbara Dewaele, Maria Debiec-Rychter
Uterus: Low-grade endometrial stromal sarcoma with t(X;17)(p11.2;q21.33) MBTD1/CXorf6
Atlas Genet Cytogenet Oncol Haematol. 2015;19(9):196-200.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Tumors/EndometrStromSarctX17ID6633.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(X;17)(p11.2;q21.33) MBTD1-CXorf67

External links

Mitelman database t(X;17)(p11.2;q21.33) MBTD1-CXorf67 [Case List]    t(X;17)(p11.2;q21.33) MBTD1-CXorf67 [Association List] Mitelman database (CGAP - NCBI)
arrayMap arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseUterus: Low-grade endometrial stromal sarcoma with t(X;17)(p11.2;q21.33) MBTD1/CXorf6
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 21 15:11:14 CET 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.